Oryzon Genomics Statistics
Total Valuation
Oryzon Genomics has a market cap or net worth of 199.39 million. The enterprise value is 211.43 million.
| Market Cap | 199.39M |
| Enterprise Value | 211.43M |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +5.73% |
| Shares Change (QoQ) | +1.56% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 54.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.17 |
| PB Ratio | 2.21 |
| P/TBV Ratio | 2.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -55.72 |
| EV / Sales | 13.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.75, with a Debt / Equity ratio of 0.19.
| Current Ratio | 0.75 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.67 |
Financial Efficiency
Return on equity (ROE) is -4.34% and return on invested capital (ROIC) is -2.77%.
| Return on Equity (ROE) | -4.34% |
| Return on Assets (ROA) | -2.61% |
| Return on Invested Capital (ROIC) | -2.77% |
| Return on Capital Employed (ROCE) | -4.64% |
| Revenue Per Employee | 162,097 |
| Profits Per Employee | -80,741 |
| Employee Count | 46 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 67.11 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +114.89% in the last 52 weeks. The beta is 0.63, so Oryzon Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +114.89% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 59.61 |
| Average Volume (20 Days) | 3,796 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oryzon Genomics had revenue of 7.62 million and -3.79 million in losses. Loss per share was -0.06.
| Revenue | 7.62M |
| Gross Profit | 7.31M |
| Operating Income | -4.66M |
| Pretax Income | -5.77M |
| Net Income | -3.79M |
| EBITDA | -4.53M |
| EBIT | -4.66M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 5.82 million in cash and 16.79 million in debt, giving a net cash position of -10.97 million.
| Cash & Cash Equivalents | 5.82M |
| Total Debt | 16.79M |
| Net Cash | -10.97M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 90.12M |
| Book Value Per Share | 1.39 |
| Working Capital | -3.10M |
Cash Flow
| Operating Cash Flow | -5.89M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 95.89%, with operating and profit margins of -61.18% and -49.81%.
| Gross Margin | 95.89% |
| Operating Margin | -61.18% |
| Pretax Margin | -75.71% |
| Profit Margin | -49.81% |
| EBITDA Margin | -59.47% |
| EBIT Margin | -61.18% |
| FCF Margin | n/a |
Dividends & Yields
Oryzon Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.73% |
| Shareholder Yield | -5.73% |
| Earnings Yield | -1.90% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Oryzon Genomics has an Altman Z-Score of 2.76. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.76 |
| Piotroski F-Score | n/a |